Compare Moderna, Inc. (MRNA) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? Moderna, Inc. trades at $136.54 (market cap $54.14B), while Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $84.39B). The key difference: Marsh & McLennan Companies, Inc. is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MRSH | |
|---|---|---|
Market Cap | $54.14B | $84.39B |
Sector | Health | Financials |
52-Week High | $174.38 | $207.02 |
52-Week Low | $22.36 | $157.32 |
Enterprise Value | $50.29B | $105.07B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The company shows solid fundamentals with revenue growth to $26.98B in 2025 and consistent earnings beats. Analyst consensus is a Buy with a $208.63 price target, though sentiment is mixed with 66.7% Hold ratings. Recent news highlights expansion in cyber protection services and insights on healthcare cost trends.
The outlook remains positive given strong profitability and strategic initiatives, but risks include economic sensitivity and competitive pressures. The stock offers upside to the consensus target, supported by institutional interest and stable cash flows, though high valuation multiples warrant caution amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
